Skip to content

Study to Validate Novel Seizure-Detection Algorithm

Validation of an Algorithm for Identification and Notification of Generalized Major Motor Seizures

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04291716
Enrollment
15
Registered
2020-03-02
Start date
2020-03-31
Completion date
2020-12-31
Last updated
2020-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy, Epileptic, Epileptic Seizures, Seizure Disorder, Seizures, Seizures, Motor

Keywords

Epilepsy, Mobile Health, Seizure, Major motor seizure, Epileptic convulsion, Epilepsy monitoring

Brief summary

The specificity and sensitivity of a novel seizure-detection mobile software application with a generalized tonic/clonic seizure detection algorithm (Motor Seizure Detection Algorithm \[mSDA\]) installed on a wearable device to be worn by the subject. The software will be tested using subjects from a patient population in an epilepsy monitoring unit (EMU) undergoing video and electroencephalograph (VEEG) observation. The number of generalized major motor seizures detected by the mSDA will be compared with those detected by VEEG.

Detailed description

Seizures are paroxysmal, abnormal behaviors which usually are associated with altered awareness and amnesia. The frequency of seizures is not easily documented. The individual who suffers from seizures may be unaware that a seizure is occurring. Many seizures, including generalized major motor seizures, have stereotyped, vigorous motor activity associated with the events. Currently, accurate seizure detection relies on EEG and video which are limited by time, size and mobility. Seizure detection can also use biomarkers such as movement patterns described by gyroscopes. These devices can monitor patterns of movement which correspond to the activity during seizures and kept in a log of seizures without patient input. The log can be used to notify patients or caregivers of seizures. This study is to determine the accuracy of a system using a commercial, wearable device linked to a computer algorithm based in the cloud which stores the movement pattern and notifies the patient and others of a generalized major motor seizure. The accuracy will be determined by a comparison of the system detections to simultaneously recorded video electroencephalogram, considered the gold standard of seizure detection.

Interventions

DEVICEMotor Seizure Detection Algorithm (mSDA)

A seizure detection algorithm installed on a propriety mobile application to be used on a commercially available watch with a gyroscope to detect movement.

Sponsors

Bracane Company
CollaboratorINDUSTRY
Overwatch Digital Health
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Intervention model description

This is a single cohort of subjects male or female, aged 18 and above who are epilepsy patients who have been admitted to an epilepsy monitoring unit (EMU).

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Provision of signed and dated informed consent form. 2. Stated willingness to comply with all study procedures and availability for the duration of the study. 3. Meets the standard of care criteria for admission to an epilepsy monitoring unit (EMU). 4. Male or female. 5. Aged 18 and above. 6. The patient has experienced at least one generalized major motor seizure prior to admission. 7. Agreement to wear a wristwatch throughout the duration of the study on the left wrist. 8. Ability to cancel false positive alarms via interaction with the application on the watch.

Exclusion criteria

1. Concurrent physiological diseases with movement disorders (Parkinson's, tremor, ataxia, Huntington's, paralysis of the upper body, pseudo-seizures). 2. Known allergic reactions to components of the (watch materials). 3. Treatment with another investigational drug or other intervention within the study 4. Children under the age of 18. 5. Women who are pregnant or nursing. 6. Inability to give consent to the study. 7. Active skin infection or rash on the upper extremities

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity1 to 5 daysNumber of major motor seizure detections by algorithm with detection by video encephalogram data.

Secondary

MeasureTime frameDescription
False positive rate1 to 5 daysTotal number of false positives and number of false positives per day.
Mean detection latency1 to 5 daysTime between algorithm detection and application notification
Notifications1 to 5 daysTotal number of seizure notifications received on subject's assigned email
Cancellations1 to 5 daysTotal number of cancellations of false positive alerts made by the subject.

Countries

United States

Contacts

Primary ContactChis Czura, PhD
chris.czura@overwatchdh.com214-662-7322
Backup ContactPamela J Nelson, PhD
pjnelson@bracaneco.com469.814.0658

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026